ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Results from the phase II ELOQUENT-3 trial demonstrate that the combination of elotuzumab plus pomalidomide and dexamethasone extended progression-free survival (PFS) compared with pomalidomide...
Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma
New results from the large phase III Myeloma XI trial confirm that maintenance therapy with lenalidomide improves progressionfree survival (PFS) over observation alone in...
BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma
In a first-in-human trial published in Lancet Oncology, the anti–B-cell maturation antigen (BCMA) antibody GSK2857916 was associated with clinical activity and was reasonably well...
Study of Single-Agent Nivolumab in Patients With Relapsed/Refractory DLBCL Fails to Meet Endpoint
Treatment with single-agent nivolumab was associated with “disappointingly low” response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to...
Combination of Ibrutinib and Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial
According to results from a phase I/II trial published in Lancet Haematology, treatment with a combination of ibrutinib and the checkpoint inhibitor nivolumab was...
Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP
Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...
An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML
According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...
Apixaban AVERTs Cancer-Associated Venous Thromboembolism
In the randomized, placebo-controlled AVERT trial, investigators assessed the safety and efficacy of apixaban thromboprophylaxis in patients with cancer considered to be at intermediate-...
Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...
For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...
Ibrutinib Plus Obinutuzumab Superior to Standard Chemoimmunotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia
Treatment with the regimen of ibrutinib plus obinutuzumab improved outcomes for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),...
Current Issue
March 2019, Volume 5, Issue 4
This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.
